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ABSTRACT 
Vascularization is crucial for solid tumor growth and invasion, providing metabolic support 
and sustaining metastatic dissemination.  
It is now accepted that ion channels and transporters play a significant role in driving the 
cancer growth at all stages. They may represent novel therapeutic, diagnostic, and prognostic 
targets for anti-cancer therapies. On the other hand, although the expression and role of ion 
channels and transporters in the vascular endothelium is well recognized and subject of 
recent reviews, only recently their involvement in tumor vascularization have been 
recognized. 
Here we review the current literature on ion channels and transporters directly involved in 
angiogenic process. Particular interest will be focused on tumor angiogenesis in vivo, as well 
as in the different steps that drive this process in vitro, such as endothelial cell proliferation, 
migration, adhesion and tubulogenesis.  
Moreover, we compare the 'transportome' system of tumor vascular network with the 
physiological one.  
 
 
INTRODUCTION  
Endothelium is a multifaceted and dynamic interface between blood components and tissues. 
Endothelial cells (EC) mediate a great number of physiological functions, including control of 
metabolism, water supply, inflammation and immune response. Consequently, several diseases are 
causally due to the deregulation of normal EC functions. The importance of vascularization in the 
tumor progression sparked hopes that manipulating this process could offer therapeutic 
opportunities [1,2]. Consequently, so far hundreds of thousands of patients benefit of antiangiogenic 
therapies that use VEGF as major drug target and approved by the US Food and Drug 
Administration. The anti-VEGF antibody (bevacizumab [Avastin]) is used in combination with 
chemotherapy, cytokine therapy or radiotherapy for several advanced metastatic cancers. 
Additionally, four multitargeted pan-VEGF receptor tyrosine kinase inhibitors have been approved: 
Sunitinib (Sutent), Pazopanib (Votrient) for metastatic Renal Cacer Carcinoma (RCC), Sorafenib 
(Nexavar) for metastatic RCC, unresectable hepatocellular carcinoma and advanced pancreatic 
neuroendocrine  tumors, and Vandetanib (Zactima) for medullary thyroid cancer [3]. On the other 
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hand, despite promising results, emerging data indicate that responses to vascular targeting therapy 
(VTT) are short-lived and resistance develops in the majority of patients. The discovery of new 
therapeutic targets is therefore necessary to provide a new input to the antiangiogenic therapy. 
Being involved in nearly all of the 'hallmarks of cancer' as defined by Hanahan and Weinberg [4], 
there is an increasing consensus on the idea that ion channels and transporters could play a 
significant role in driving cancer progression at all stages. Therefore they may be seen as potential 
novel therapeutic, diagnostic, and prognostic targets for anti-cancer therapies. 
Nonetheless, although the expression and role of ionic channels and transporters (collectively 
indicated as “trasportome”) in the vascular endothelium is well recognized and subject of a number 
of recent reviews [5–8], ‘trasportome’ entered only recently as major players in tumor 
vascularization [9,10]. 
Here we collect and discuss current literature focused on ion channels and transporters directly 
involved in angiogenic process. Moreover, starting from a critical review of the experimental data 
obtained so far in vitro and in vivo, we will try to define the most promising checkpoints at which 
tumor vascular 'transportome' differs from the physiological one.  
 
VOLTAGE-GATED CHANNELS  
Although EC are generally described as non excitable cells, a number of experimental evidences 
suggest a role for voltage dependent channels (VOCs) in both cultured and freshly isolated EC [10]. 
On the other hand, the role of VOCs in tumor progression has been largely described and different 
data point to Na+, K+ and Ca2+ channels as key players, suitable to be specifically potential target 
in clinical treatments [11]. 
K+ channels (KV) attracted most of the work in oncology since the early discovery unveiling their 
role in the control of cell proliferation [12,13]. Ether-á-go-go-1 (EAG1, KCNH1, KV10.1) is a 
CNS-localized voltage-gated K+ channel that is found ectopically expressed in many solid tumors. 
Most of the interest in KV10.1 arises from its expression in up to 70% of tumor cell lines and human 
cancers [13]. Monoclonal antibodies against human EAG1, developed by Stuhmer’s and Pardo’s 
groups, might represent a suitable tool in cancer therapy [14]. KV10.1 expression might offer an 
advantage to tumors through increased vascularization and resistance to hypoxia: indeed, EAG1 
regulates cellular oxygen homeostasis, increasing HIF-1 activity, and thereby VEGF secretion and 
tumor vascularization [15]; accordingly EAG1 silencing inhibits tumor growth and angiogenesis in 
osteosarcoma  in vivo [16] (Table 1 and Fig.1).  
A promising issue is related to other K+ channels, such as human ether-a-gogo related gene-1 
(hERG1)-Kv11 [13,17,18]; Pillozzi and coworkers showed that hERG1 channels regulate vegf-a 
expression and VEGF-A secretion in cancer cells potentially promoting angiogenesis [19]. 
Moreover, it has been discovered a correlation between the levels of VEGF-A, hERG1 and 
microvessel density and proliferation-related parameters in two cases of bilateral retinoblastoma 
patients [20]. Beside the role of KV10 and KV11, KV 1.3 channels are involved in VEGF-mediated 
HUVEC proliferation: VEGF-mediated hyperpolarization via Margatoxin (MTX)-sensitive KV 
channels causes a Ca2+ entry, leading to an increase in NO synthesis, finally resulting in EC growth 
enhancement [21] (Table 1 and Fig.1). All together, the data point out an important role for K+ 
channels in the cross talk between cancer cells and tumor endothelium by induction of VEGF 
release that in turn promotes neovascularization. This particular function of K+ channels makes 
them clinically interesting as potential targets to promote vascular “normalization” by interfering 
with VEGF signaling during a critical window of the antiangiogenic treatments (see also the 
conclusion section). 
Voltage-gated Na+ channels (VGSCs) are also expressed in non excitable cells and functionally up-
regulated in metastatic tumor cells [22–24]. Recently, a clear relationship between functional 
expression and biological role of VGSCs in EC has been described [25]. Molecular expression 
analyses and electrophysiology revealed consistently that the main functional VGSC isoforms in 
HUVEC are Nav1.5 and Nav1.7. VGSC activity potentiates VEGF-induced ERK1/2 activation by 
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attenuating membrane depolarization, altering [Ca2+]i kinetics and PKC activity with a consequent 
increase in cellular proliferation, chemotaxis, and tubulogenesis [25] (Table 1 and Fig.1). Although 
the question on the specificity of VGSC on VEGF signaling pathway remains to be elucidated, the 
data unveil an intriguing mechanism for the control of Vm in non-excitable cells by VGSCs in 
response to physiological stimuli in vitro. 
As regarding voltage-gated Ca2+ channels (VGCCs), most of the studies have been conducted on 
human breast carcinoma cell lines, which actually express VGCCs, mainly of the T-type [26–28]. 
Nevertheless, the role and expression of VGCCs in endothelium is still debated [3,7,24]. 
Conflicting data could arise from the use of different cultured EC lines and their well known 
variable behaviour (see also the conclusion section for a more detailed discussion). In human 
umbilical vein EC (HUVEC) Angiotensin II stimulates Ca2+ influx via CaV and promotes cell 
migration [30]. On the other hand, CaV expressed by VSMCs could play an anti-angiogenic role 
through indirect effects on EC: nifedipine, a widely used inhibitor of L-type calcium channels, 
stimulates VEGF production from human coronary smooth muscle cells, an effect abolished by 
PKC inhibitors and a bradykinin B2 receptor antagonist [31] (Table 1 and Fig.1). 
 
TRANSIENT RECEPTOR POTENTIAL (TRP) PROTEINS AND STIM1-ORAI1 
COMPLEX.  
Transient Receptor Potential (TRP) channels trigger Ca2+ signals that control intracellular events 
involved in the initiation and progression of cancer. It is not therefore surprising that the expression 
and function of some TRP proteins are altered during tumor growth and metastasis [9,32].  
TRPs are widely expressed in endothelium and their activity has been related to normal and tumor 
vascularization [5,6]. TRP -mediated Ca2+ influx can be triggered by the release from intracellular 
Ca2+ stores giving rise to store-operated Ca2+ entry (SOCE). An alternative route is the store-
independent Ca2+ entry (NSOCE) [33]. 
VEGF mediates NSOCE through TRPC6 channels in human microvascular EC [34,35]. Dominant 
negative TRPC6 significantly reduces EC number, migration and sprouting [36]. Moreover, TRPC6 
promotes both proliferation and tubulogenesis induced by VEGF, but not bFGF, in HUVEC [37]. 
Phosphatase and tensin homolog (PTEN) regulates cell surface expression of TRPC6, and 
consequently Ca2+ entry, endothelial permeability, and angiogenesis in human pulmonary EC [38]. 
Nonetheless, TRPC6 can also exert its proangiogenic role indirectly through its activity on cancer 
cells being a key mediator hypoxia-mediated notch-driven growth and invasiveness of glioblastoma 
multiforme (GBM): inhibition of the hypoxia upregulated TRPC6 expression and NFAT activation 
in glioma cells, markedly reduced the number of branch points in EC grown in conditioned medium 
harvested from glioma cells, indicating that TRPC6 is essential for the angiogenic potential of 
glioma cells [39] (Table 1 and Fig.1).  
Other groups reported a role of VEGF-mediated SOCE due to TRPC1 in the enhancement of 
HMVEC and HUVEC permeability [40–42]. Remarkably, TRPC1 is proangiogenic in vivo. 
Knockdown of zebrafish TRPC1 by morfolinos caused severe angiogenic defects in intersegmental 
vessel sprouting, presumably due to impaired filopodia extension during EC migration [43] (Table 
1 and Fig. 1).  
This apparently surprising ability of VEGF to couple to different channels responsible for SOCE or 
NSOCE could simply depend on tissue variability, especially between small capillaries and large 
vessels. Accordingly, the pattern of TRPC channels expressed in HMVEC and HUVEC is different, 
TRPC4 being undetectable in HMVEC [36].   
Besides TRPC1 and TRPC6, also Orai1 and STIM1, components of the so-called calcium release 
activated currents (CRAC) channels, concur to the VEGF-mediated SOCE in HUVEC [44,45]. 
VEGF stimulation promotes STIM1 clustering which in turn activates Orai1 [45]. Moreover, 
knock-down of Orai1 inhibits VEGF-mediated HUVEC migration, proliferation and tubulogenesis 
[44–46]. On the other hand, Trebak and coworkers reported recently that the thrombin-induced 
decrease in EC permeability requires STIM1, but is unrelated to Orai1 and Ca2+ entry across the 
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plasma membrane [47] (Table 1).   
Interestingly, STIM1, as well as TRPC1 and TRPC4 knockdown, inhibits tube formation in both 
HUVEC and EA.hy926 cells, an EC line derived from HUVEC fused with human lung 
adenocarcinoma cell line A549 [48]. Since Orai1 and TRPC1 can functionally interact at least in 
some models, the TRP- and Stim/Orai- pathways may give rise to a complex signaling network 
underlying proangiogenic calcium signals [49].  
Since VEGF regulates several activities in EC, the discovery of a specific role for the different 
channels in selected cell functions, such as migration and proliferation on one side or permeability 
on the other, could be a more useful molecular target than the broad VEGFR inhibitors (see also 
Conclusion section).  
TRPV4 is another emerging player in angiogenesis. The availability of high selective antagonists 
for this channel makes it a promising molecular target for antiangiogenic treatments [50]. TRPV4 is 
widely expressed in the vascular endothelium where it acts as a mechanosensor during changes in 
cell morphology, cell swelling and shear stress [50–53]. A study conducted both in vivo and in 
cultured EC reports that both shear stress and agonist-activation of TRPV4 enhance EC 
proliferation as well as collateral growth after arterial occlusion [54]. Recently, we showed a key 
role for TRPV4 in tumor-derived EC (TEC) migration (better discussed below) [55] (Table 1 and 
Fig.1). It is worth noting that the dynamics of a single TRP should be considered in a more 
integrated framework: for instance, the trafficking to the plasma membrane of TRPV4-TRPC1 
heteromeric complex is enhanced by Ca2+ store depletion in HUVEC, resulting in an enhanced 
Ca2+ influx upon exposure to shear flow [56].  
A number of cellular stress factors, including hypoxia, nutrient deprivation, and reactive oxygen 
species, are important stimuli for angiogenic signaling [57]. TRPM2 promotes macrovascular 
pulmonary EC permeability in a H2O2-dependent manner. TRPM2 knockdown or overexpression 
of the TRPM2 short isoform (that acts as dominant negative for TRPM2 long isoform) 
significantly reduced the H2O2/Ca2+-mediated increase of paracellular permeability and cell 
death in H5V EC [58,59] (Table 1 and Fig.1). These data open the exciting possibility of targeting 
TRPM2 for endothelial protection against ROS-induced cell damage.  Additionally, the same 
strategy could be employed for treatment of malignant tumors, because TRPM2 isoforms are 
expressed in different tumors, and at least one of them may function as a tumor enhancer [60]. 
Finally, TRPM7, a Ca2+ and Mg2+ permeable channel that regulates Mg2+ homeostasis, is 
involved in a number of vascular disorders such as hypertension and dysfunction of endothelial 
and smooth muscle cells [61]. A notable structural feature of TRPM7 is the presence of a kinase 
domain at its C-terminus, making TRPM7 unique amongst ion channels, and allowing its 
involvement both in cellular Mg2+ homeostasis and broad signaling [62]. TRPM7 acts negatively 
on HUVEC proliferation and migration, whereas its functions on HMEC seem to be different [63–
65] (Table 1 and Fig.1). Once again, more studies are required to better understand the variability 
of the effects induced by TRPM7 silencing in vascular endothelium.  
In addition to the canonical angiogenesis, tumor vascularization may be supported by bone 
marrow (BM)-derived endothelial progenitor cells (EPCs) incorporating within sprouting 
neovessels. This feature hinted at EPC inhibition as a novel therapeutic target to pursue along 
with anti-angiogenic treatments [1,57]. Suppression of Orai1 in EPC prevents SOCE and tubule 
formation [45,66]. Moreover, EPCs isolated from RCC patients (RCC-EPCs) display an increased 
SOCE, which correlates with Orai1, Stim1, and TRPC1 overexpression as compared to EPCs 
from healthy patients: genetic suppression of Stim1, Orai1, and TRPC1 affects SOCE in RCC-
EPCs [67]. TRPC1 regulates proliferation and migration of EPCs isolated from rats bone marrow 
[68] (see also Table 1 and Fig.1).  
 
NICOTINIC RECEPTORS 
nAChR are homo- or hetero-pentameric ion channels activated by endogenous acetylcholine or 
exogenous agonists like nicotine [69]. EC express most of the known mammalian nAChR subunits 
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[70–72]. In particular α7 nAChR mediates the main effects of nicotine on EC, such as proliferation, 
survival, migration, tube formation, and intracellular signaling (calcium and NO signals, 
phosphorylation events and gene transcription). Interestingly, α9 and α7 nAChRs exert opposing 
effects on nicotine-induced cell proliferation and survival [72–74]. 
Exposure to nicotine up-regulates α7-nAChR and pharmacological inhibition of α7-nAChR by 
Mecamylamine or α-Bungarotoxin significantly and reversibly reduces EC tubulogenesis in vitro. 
Even more importantly, pharmacological inhibitors or genetic disruption of α7-nAChR significantly 
suppress neo-angiogenesis in inflammation, ischemia, and neoplasia in several models. The 
angiogenic effect of nAChR is exerted through MAPK, PI3K/Akt, and NF-kB pathway; however, 
since nAChR-mediated angiogenesis is only partially inhibited in α7-nAChR-deficient mouse, other 
nAChR isoforms are presumably involved [72]. Nicotine triggers neo-angiogenesis in breast, colon 
and lung tumor cells implanted in chick chorioallantoic membranes and promotes b-FGF release 
through the recruitment of nicotinic receptor,  v 3 integrin, and MAPK pathway [75–77]. The 
ability of nicotine to promote late EPCs proliferation, migration, adhesion, and tubulogenesis 
strongly suggests that its role is not restricted to mature EC [78] (Table 1 and Fig. 1) 
 
VOLUME-REGULATED ANION CHANNELS 
Resting normal EC expresses volume-regulated anion channels (VRACs), mainly permeable to 
chloride ions and activated by osmotic cell swelling and shear stress. Endothelial VRACs are open 
in resting conditions and contribute to the maintenance of the resting potential in non-stimulated 
cells, in addition to K+ channels [10].  
VRAC blockers (Mibefradil, NPPB, Tamoxifen, and Clomiphene) inhibit tube formation of rat and 
human microvascular EC and are strongly antiangiogenic in vivo [79] (Table 1). Although the 
mechanism of VRACs involvement in angiogenesis has not been clarified yet, one possible 
explanation is that VRAC activation could lead to an increase of the driving force for Ca2+ entry 
into the cell, thus affecting the intracellular Ca2+ concentration.  
 
WATER CHANNELS 
Aquaporins (AQPs) allow passive water flow in response to local osmotic gradients. They 
contribute to epithelial secretion and absorption, and cell volume regulation. Ectopic AQP 
expression is associated with several human cancers [12,80]. A number of reports point to AQP, 
mainly AQP1, involvement in cell motility and tumor vascularization [81–83]: its expression in 
tumor cells and their vasculature is variable being dependent not only on the origin of the tumor, 
but also on its location in the host animal. This observation strenghtens the strong inductive role of 
the microenvironment on tumor features.  
Interestigly, AQP1 is upregulated in human brain tumors: little or no AQP1 expression is found in 
normal human brain microvessel endothelium, consistently with its general low permeability. On 
the other hand, AQP1 expression in the vasculature increases with the progression from normal 
brain to low-grade to high-grade astrocytoma [84].  
Verkman and coworkers provided direct evidence for AQP1 role in angiogenesis in vivo by 
implanting melanoma cells in AQP1 null mice and syngenic mice lacking AQP1 [85]. In both cases 
the authors observed a markedly lower density of microvessels and the presence of islands of viable 
tumor cells surrounded by necrotic tissue compared to control mice. Functional analyses on mouse 
aortic EC isolated from AQP1 null mice and wild type mice revealed an impaired migration, 
invasiveness and capability to form capillary-like structures in matrigel [85]. On the other hand, 
RNA interference experiments performed by intratumoral injections of AQP1 siRNAs in a mouse 
model of melanoma suggest that AQP1 inhibition can humper tumor growth significantly lowering 
microvessel density [86]. AQP1 is also overexpressed in both human and rodent chronic liver 
disease. Its overexpression during cirrhosis is localized to the altered neovasculature. AQP1 
promotes angiogenesis, fibrosis, and portal hypertension through mechanisms dependent on 
osmotically sensitive microRNAs, as revealed on human and mouse hepatic EC [87]. Finally, 
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microvessel overexpression of AQP1 is associated with bone marrow angiogenesis in patients with 
active multiple myeloma [88] (tab 1 and Fig.1). 
 
CARRIERS 
Beside the role of ion channels, extensive evidence points out the involvement of carriers and 
transporters in tumor progression [89,90]. We will focus on sodium-proton exchanger and sodium-
calcium exchanger, the best studied so far for their involvement in tumor progression and 
vascularization (Table 1 and Fig.1).  
Sodium-proton exchanger (NHE). It is well recognised that pathological elevations of pHi can 
concur to some functional features of malignant cells [91]. All tumors share an altered regulation of 
hydrogen ion dynamics and tumor progression correlates with the peculiar acid-base balance in 
cancer cells: an extracellular acid microenvironment (pHe) linked to an alkaline intracellular pH 
(pHi). Indeed, tumor cells have alkaline pHi values in the range of 7.12-7.7 vs 6.99-7.05 of normal 
cells, while producing acidic pHe values of 6.2-6.9 vs 7.3-7.4 of normal cells. This reversed pH 
gradient across the cell membrane increases with tumor progression. Since NHE is a universal and 
conserved regulator of cellular proton balance, it received great attention. Through its action the 
inwardly directed Na+ gradient can drive the uphill extrusion of protons that drives pHi 
alkalinization and pHe acidification [91].  
The highly hypoxic tumor microenvironment hyperactivates NHE1 and, since specific NHE1 
inhibitors (Cariporide) are available, some authors propose them for innovative combination trials 
with antiangiogenic drugs. Low concentrations of Cariporide can lead to a decrease in pHi and 
down-regulation of VEGF. Moreover, exposure to cariporide inhibits HUVEC proliferation and 
migration promoted by conditional medium from K562 leukemia cells. In vivo experiments directly 
confirmed that inhibition of NHE1 by Cariporide could affect tumor growth and angiogenesis. 
Tumor regression is thus presumably a result of the decreased microvessel density, which causes 
insufficient oxygen and nutrients supply [92]. Blocking NHE1 reduces VEGF release from the 
tumor cells suggesting that, in addition to being stimulated by hypoxia, VEGF production and 
angiogenesis are linked to acidic pHe and to the NHE1-dependent changes in pH [93]. Systemic 
Amiloride perfusion also reduced neovascularization experimentally induced in an animal model, 
probably through inhibition of NHE1 [94].  
Sodium-calcium exchanger (NCX). Sodium influx mediated by non-selective cation channels can 
drive to its accumulation beneath the plasma membrane. This event may increase [Ca2+]i by locally 
inverting (3Na+ out : 1 Ca2+ in) the operation mode of NCX [95]. 
An intriguing example has been described in HUVEC, in which a coupling between NCX and 
voltage-dependent sodium channels (VGSCs) occurs. As previously stated, VGSC activity 
promotes VEGF-induced proliferation, chemotaxis, and tubular differentiation and decreases 
adhesion to substrate [25]. Moreover, Ca2+ inflow through reverse mode NCX is required for PKC 
activation and targeting to the plasma membrane, as well as for VEGF-induced ERK1/2 
phosphorylation and downstream EC functions in angiogenesis [96]. 
 
CA2+ SIGNALS, ION CURRENTS AND CHANNELS IN TUMOR-DERIVED 
ENDOTHELIAL CELLS. 
As previously stated, a possible reason for the failure of the antiangiogenic therapies may be the 
high instability of EC within the tumor. It is now well established that normal and altered EC are 
highly heterogeneous in structure and function, due to genetic modifications and the variability of 
the local microenvironment [97–100]. The basic properties of EC obtained from different human 
tumors (tumor-derived EC, TEC) have been investigated only recently by a limited number of 
groups [101–103]. Breast tumor vessels display differential expression of over 1000 genes when 
compared with normal vessels, as revealed by gene array analysis [104]. Affymetrix microarray 
analysis of laser-captured CD31-positive blood vessels identified 63 genes that are upregulated 
Page 6 of 22
http://mc.manuscriptcentral.com/issue-ptrsb
Submitted to Phil. Trans. R. Soc. B - Issue
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Review Only
significantly (5–72 fold) in angiogenic blood vessels associated with human invasive ductal 
carcinoma of the breast as compared with blood vessels in normal human breast [105].  
On the other hand, TEC have been isolated and cultured from human kidney and breast carcinomas 
on the basis of membrane markers and exhibit altered genotype, gene expression, phenotype, and 
function. They are often aneuploid and display chromosomal instability. In addition, TEC avoid 
senescence, a process typical of normal EC, and display enhanced proliferation, motility, and ability 
to organize into capillary-like tubules [101,106,107]. Moreover, EC from human breast cancer are 
significantly more radiosensitive than their normal counterparts from the same patients [108]. A 
recent report compared the characteristics of two types of human TEC from high-metastatic (HM) 
and low-metastatic (LM) tumors: HM-TEC showed higher proliferative and invasive activity than 
LM-TEC [109]. 
Tumor-derived blood vessels are capillary structures and therefore TEC can be truly considered as 
altered microvascular EC. They can be compared to ‘physiological’ microvascular EC and thus the 
best choice would be the use to human microvascular EC obtained from the same ‘healthy’ tissue of 
TEC. Unfortunately, it is often very difficult to isolate and maintain in culture microvascular EC 
from all human healthy tissues: therefore dermal human microvascular EC (HMEC) are often used 
as a physiological counterpart. Conversely, macrovascular EC, such as HUVEC, are a less suitable 
choice, due to their features highly divergent from microvascular endothelium.  
In the last years, our group provided substantial evidence that TEC-mediated (mainly Breast cancer-
derived TEC, BTEC, and more recently renal-TEC, RTEC) intrcellular signaling pathways linked to 
Ca2+ signals are quite different from that observed in normal human microvascular EC (Fig. 2). We 
investigated in detail the differential effects of intracellular Ca2+ signaling regulated by the 
complex and networking pathways involving arachidonic acid (AA), Nitric Oxide (NO) and 
Hydrogen Sulfide (H2S), key-intracellular messengers triggered by proangiogenic factors (VEGF, 
bFGF) in vascular EC [6]. Low micromolar AA concentrations trigger NO release and protein 
kinase A (PKA)-dependent Ca2+ entry which in turn stimulate BTEC migration and tubulogenesis 
in vitro [110,111]. AA-dependent Ca2+ signals are intriguingly related to the tubule maturation 
stage, being downregulated in the late phases of the process [55,112]. On the other hand, AA failed 
to induce any pro-migratory effect in HMEC, with consistent significantly smaller Ca2+ signals 
compared with BTEC [113] (Fig. 2).  
Notably, both the tubulogenic and promigratory effects induced by AA are highly sensitive to 
carboxyamidotriazole (0.1 µM CAI), a well known inhibitor of agonist-activated Ca2+ entry 
[112,114]. CAI affects proliferation, invasion, metastasis, and neovascularization both in vitro and 
in vivo. Combined to other compounds, it reduces the growth of cholangiocarcinoma, melanoma, 
colorectal, lung, pancreatic, ovarian and breast cancer [6]. Since CAI is effective from 1 µM on 
normal EC, the higher sensitivity of BTEC to this compound could be suitable to increase the 
efficacy of antiangiogenic agents and to reduce their secondary effects in combination therapies. 
Higher doses of CAI exert antiangiogenic activity in different systems such as mouse presenting 
ischemic retinopathy, rat aortic ring culture, or chorioallantoic membrane [112].  
H2S is a recently discovered gasotransmitter [115,116] involved in angiogenesis regulation,  
particularly via VEGF signaling [117]. H2S activates Ca2+-permeable non-selective channels in a 
subpopulation of BTEC and the following Ca2+ is enhanced in BTEC compared to HMEC. 
Remarkably H2S mediates tumor proangiogenic signaling triggered by VEGF: B-TEC pretreated 
with DL-propargylglycine, an inhibitor of the H2S-producing enzyme cystathionine γ-lyase, 
showed drastically reduced migration and Ca2+i signals induced by VEGF.[117] (Fig. 2). H2S 
donors also activate ATP-dependent K+ (KATP) channels both in normal EC and in BTEC [117–
120]. This evidence is of particular interest since during ischemic/hypoxic conditions, typical of the 
initial phases of cancer progression, KATP channels act as ATP sensors.  
We recently provided strong evidences about the role of TRPV4 channels in promoting AA-
mediated TEC migration: TRPV4 channels, are upregulated in BTEC and RTEC as compared with 
dermal HMEC and normal kidney glomerular EC [55]. AA-activated TRPV4 is essential for BTEC 
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migration: loss of TRPV4 expression results in decreased Ca2+ responses to the TRPV4-specific 
agonist 4α-phorbol 12,13-didecanoate and in complete inhibition of AA-induced BTEC migration. 
The mechanism by which AA regulates TRPV4 was also revealed in BTEC. AA induces actin 
remodeling, which triggers TRPV4 recruitment in the plasma membrane: the consequent Ca2+ 
entry finally leads to BTEC migration [55]. 
However, as previously stated, TRPV4 is ubiquitary in healthy vascular endothelium and plays a 
physiological role both in large arteries and microvessels: these relevant activities require careful 
consideration of its therapeutic potential. On the other hand, an overexpression on TEC could be 
exploited for a tumor targeted therapy based on lower inhibiting doses of TRPV4 antagonists which 
could selectively affect TEC and not normal EC. 
 
 
CONCLUSIONS 
Since the seminal hypothesis proposed by Judas Folkman in ’70, interference with tumor 
vascularization is considered a key therapeutic opportunity in cancer treatment [2].  
Unfortunately, despite promising results, vascular targeted therapy (VTT) appear short lived and 
resistance develops in the majority of patients [121]. The relative inefficacy of VTT maybe due to 
several reasons.  
More suitable preclinical cancer models are needed in oncological practice. As previously stated, 
vessels in cancer significantly differ from normal vasculature and the instability of EC within the 
tumor is a relevant feature. To this purpose, the use of TEC seems a more appropriate model 
compared to the normal EC.  We expect that more detailed studies on the “transportome” in tumor 
vascularization using the aforementioned models (beside the EC models already in use) will give 
new input in unveiling the differences in signaling, transcriptome profiles, and vascular ‘‘ZIP 
codes’’ and will likely prove to be important for understanding the conversion of normal 
endothelial cells into tumor-associated endothelial cells. As a preliminary example, overexpression 
of TRPV4 in TEC [55] could be useful for selectively targeted therapy using lower doses of channel 
antagonists which affect TEC reducing seondary undesired effects on normal EC. 
Another high priority challenge is the research of novel molecular anti-vascular targets (related or 
unrelated to VEGF signaling). The evaluation of their clinical potential, in particular as combination 
therapy with current VEGF (receptor) inhibitors, is likely to expand the antiangiogenic 
armamentarium. In particular it could be useful to narrow the field of action for VEGF-mediated 
targeted therapy. In this context, the recent interest on human ‘transportome’ involvement in tumor 
vascularization is a promising field, since several members are activated downstream the 
recruitment of VEGF receptors. For example, whereas the interference with the bulk VEGF 
signaling alters the activity of a moltitude of different cells and functions, targeting TRPC6 or Orai1 
may only affect EC migration and proliferation [36,37,39,45,66], while TRPC1 and STIM1 may 
selectively influence vascular permeability [40–42,47].  
It is worth noting that channels and transporters are widely distributed and ubiquitous. This feature 
has to be carefully taken in account when considering them as clinical targets. This problem could 
be overcome by directed targeted therapies taking advantage from nano-biomedicine: for example, 
nanoparticle functionalization with peptide cyclic RGD for angiogenesis-specific targeting [122] 
together with a specific channel modulator could be successfully employed.  
On the other hand, the ubiquitous expression of the channels could be used as a positive feature, due 
to the redundancy of the signaling pathways which regulates the different hallmarks of cancer: in 
other words, the use of specific channels to selective co-target different key steps of carcinogenesis 
beside tumor vascularization, could result in more effective and long lasting therapies. For example, 
TRPC6 channels targeting could affect VEGF release from tumor cells as well as EC migration and 
tumor vascularization [36,37,39]. 
Another important issue is the therapeutic potential of sustained vessel normalization to suppress 
metastasis and enhance chemotherapy. Indeed, several preclinical studies have revealed that the 
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high levels of VEGF in tumors induce vessel abnormalities. It is reasonable to postulate that these 
vessel abnormalities could be decreased by lowering VEGF signaling. VEGF-targeted therapy 
induces characteristic features of vessel normalization, including reduced number and size of 
immature tumor vessels and increased pericyte coverage, together with decreased permeability, 
oedema and interstitial fluid pressure [123]. Interfering with K+ channels, such as EAG1 and 
hERG1, TRPC6 channels or NHE exchanger on tumor cells could be useful to promote vascular 
“normalization” by interfering with VEGF signaling during a critical window of the antiangiogenic 
treatments . 
 
Finally, even if big efforts have been produced in the last years in order to characterize and study 
the involvement of transportome in cancer cell biology, and in particular in tumor vascularization, 
the field is relatively novel. The scientific interest on this topic is largely increasing as pointed out 
by PubMed search. The research on transportome and cancer is expected to expand even more in 
the next decade, and we believe that the oncogenic roles of channels, as well as the molecular 
mechanisms responsible for their regulation, will be largely unveiled. 
 
FIGURE LEGEND 
Table 1 
Ion Channels and carriers involved in the different phases of angiogenesis. HMEC, human 
microvascular EC; HPAEC, human pulmonary artery EC; HUVEC, human umbilical vein EC; 
EA.hy926, EC line derived from HUVEC fused with human lung adenocarcinoma cell line A549; 
PAEC, porcine aortic endothelial cells; BTEC, tumor derived EC from breast carcinoma; H5VEC, 
heart endothelioma (H5V) EC; MAEC, mouse aortic EC; EPC, endothelial progenitor cells; RCC-
EPC, EPC isolated from renal carcinoma patients; Numbers in parenthesis indicate the respective 
reference number.  
 
Figure 1 
Schematic representation of channels/transporters role in the different key steps of tumor 
vascularization. The mechanisms are presented in representative EC, SMC, EPC and tumors 
without any tissue specification. EC, endothelial cells; EPC, endothelial progenitor cells; VSM, 
vascular smooth muscle cells; MAPK, mitogen-activated protein kinase; PI3K, 
Phosphatidylinositide 3-kinases; AKT, protein kinase B; NF-kB, nuclear factor kappa-light-chain-
enhancer of activated B cells; bFGF, basic Fibriblast Growth Factor; VEGF, Vascular Endothelium 
Growth Factor; VEGFR, VEGF Receptor; NFAT, Nuclear factor of activated T-cells; PAR, 
protease-activated receptors; PTEN, Phosphatase and tensin homolog; PKC, protein kinase C. 
 
Figure 2 
A. Schematic representation of the differences between normal endothelial cells (EC) and tumor 
derived endothelial cells (TEC) in terms of Ca2+-related intracellular signaling pathways. 
Arachidonic Acid (AA), Nitric Oxide (NO) and Hydrogen sulfide (H2S)-promoted Ca2+i signals 
are significantly upregulated in TEC compared with EC. These differences are at least in part due to 
TRPV4 overexpression and consequent TEC migration. B. Schematic representation of the signal 
transduction pathway involved in proangiogenic Ca2+ signals in TEC: (1) AA-mediated actin-
remodeling promotes TRPV4 vesicles to traffic and insert in the plasma membrane; as a 
consequence, more functional channels allow Ca2+ entry required for TEC migration. (2) 
Activation of endothelial NO synthase (eNOS) mediated by AA-mediated protein kinase A (PKA) 
promotes NO release and consequent Ca2+ entry via unknown channels. (3) VEGF promotes 
promigratory Ca2+ signals mediated by H2S via cystathionine γ-lyase (CSE). 
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